3-METHYLGLUTACONIC ACID manufacturers
- 3-METHYLGLUTACONIC ACID
-
- $0.00 / 25KG
-
2025-03-21
- CAS:5746-90-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
|
| | 3-METHYLGLUTACONIC ACID Basic information |
| Product Name: | 3-METHYLGLUTACONIC ACID | | Synonyms: | 3-METHYL-PENT-2-ENEDIOIC ACID;3-METHYLGLUTACONIC ACID;3-METHYL-2-PENTENEDIOIC ACID;3-Methyl-delta^2-penten-1,5-dioic acid;glutacouic acide 3-methyl;3-Methylglutaconic acid, mixture of E and Z isomers;NSC 249232;(E)-3-methylglutaconic acid | | CAS: | 5746-90-7 | | MF: | C6H8O4 | | MW: | 144.13 | | EINECS: | | | Product Categories: | | | Mol File: | 5746-90-7.mol |  |
| | 3-METHYLGLUTACONIC ACID Chemical Properties |
| Melting point | 115 °C | | Boiling point | 399.4±25.0 °C(Predicted) | | density | 1.307±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 4.36±0.10(Predicted) | | color | White to Light Beige | | BRN | 1722907 | | Stability: | Hygroscopic |
| | 3-METHYLGLUTACONIC ACID Usage And Synthesis |
| Uses | 3-Methylglutaconic acid is a glutarate which builds up in the urine in 3-methylglutaconic aciduria. 3-methylglutaconic aciduria is a term used to describe five different disorders that impair the functioning of energy-producing centers within cells (mitochondria) | | Definition | ChEBI: A dicarboxylic acid comprising (E)-glutaconic acid carrying a 3-methyl substituent. | | Biological Activity | 3-Methylglutaconic acid is a metabolite (as the CoA thioester) in the leucine degradative pathway as well as the mevalonate shunt, a pathway th at links isoprenoid metabolism with mitochondrial acetyl-CoA metabolism. 3-Methylglutaconic acid accumulates in patients with a deficiency of 3-methylglutaconyl-CoA hydratase. | | in vivo | | Animal Model: | Male Sprague-Dawley rats and male Hartley guinea-pigs[2] | | Dosage: | 0.16 mL/kg, 90 min | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Increased initial blood pressure and heart rate in rats followed by vagal bradycardia and hypotension (rat)
Developed three patterns of cardiovascular changes (Type 1: a period of sympathetically-mediated hypertension and tachycardia followed by vagal bradycardia; Type 2: Increased arterial pressure and heart rate, but no vagal activation; Type 3: exhibited no significant cardiovascular changes(Guinea-pigs).
|
| Animal Model: | Male Wistar rats[3] | | Dosage: | 45mg/kg for single dose, 4days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Decreased in NR2B expression on the whole cerebellum tissue and Purkinje cells.
|
|
| | 3-METHYLGLUTACONIC ACID Preparation Products And Raw materials |
|